Xeris Biopharma Holdings Inc Investor Relations Material

Xeris Biopharma Holdings, Inc. (Xeris) is a biopharmaceutical company that engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's product development efforts include developing and commercializing drugs for patients with type 2 diabetes mellitus (T2DM). Its lead drug candidate is XER-0212, a next-generation insulin sensitizer for the treatment of T2DM. In addition to XER-0212, the company's product pipeline includes other next-generation insulin sensitizers for the treatment of T2DM.